Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event

H. Pakdaman, M. A. Sahraian, A. Fallah, R. Pakdaman, K. Ghareghozli, M. Ghafarpour, E. Rahimian, A. Shirani

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Background - A new treatment approach to multiple sclerosis (MS) is the initiation of interferon therapy in the early phase of the disease when a patient presents with clinically isolated syndrome. Aims of the study - The goal of this study was to assess the effect of early treatment on the risk of conversion to clinically definite MS in Iranian patients. Methods - Eligible patients had presented with a first episode of neurological dysfunction suggesting MS within the previous 3 months and had abnormal brain magnetic resonance imaging (MRI). Patients were randomly assigned to receive intramuscular interferon beta 1a 30 μg or placebo once a week for 3 years. Results - Of the 217 patients randomized, 202 patients completed the study; 104 received Avonex and 98 received placebo. Fewer patients converted to clinically definite multiple sclerosis in the treated group than in the placebo group during the study (36.6% vs 58.2%, P < 0.003). The number of active T2-weighted MRI lesions was significantly lower in the treated group. Conclusions - The results of our study, which are consistent with those from western studies, show that treatment at an early stage of MS delays conversion to definite MS and has positive effects on MRI outcomes.

Original languageEnglish (US)
Pages (from-to)429-431
Number of pages3
JournalActa Neurologica Scandinavica
Volume115
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Multiple Sclerosis
Placebos
Magnetic Resonance Imaging
Therapeutics
Interferon beta-1a
Interferons
Brain

Keywords

  • Clinically isolated syndrome
  • Interferon beta-1a
  • Interferon treatment
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. / Pakdaman, H.; Sahraian, M. A.; Fallah, A.; Pakdaman, R.; Ghareghozli, K.; Ghafarpour, M.; Rahimian, E.; Shirani, A.

In: Acta Neurologica Scandinavica, Vol. 115, No. 6, 01.06.2007, p. 429-431.

Research output: Contribution to journalReview article

Pakdaman, H. ; Sahraian, M. A. ; Fallah, A. ; Pakdaman, R. ; Ghareghozli, K. ; Ghafarpour, M. ; Rahimian, E. ; Shirani, A. / Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. In: Acta Neurologica Scandinavica. 2007 ; Vol. 115, No. 6. pp. 429-431.
@article{f173991c8de54586834de6cd2ecbca0d,
title = "Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event",
abstract = "Background - A new treatment approach to multiple sclerosis (MS) is the initiation of interferon therapy in the early phase of the disease when a patient presents with clinically isolated syndrome. Aims of the study - The goal of this study was to assess the effect of early treatment on the risk of conversion to clinically definite MS in Iranian patients. Methods - Eligible patients had presented with a first episode of neurological dysfunction suggesting MS within the previous 3 months and had abnormal brain magnetic resonance imaging (MRI). Patients were randomly assigned to receive intramuscular interferon beta 1a 30 μg or placebo once a week for 3 years. Results - Of the 217 patients randomized, 202 patients completed the study; 104 received Avonex and 98 received placebo. Fewer patients converted to clinically definite multiple sclerosis in the treated group than in the placebo group during the study (36.6{\%} vs 58.2{\%}, P < 0.003). The number of active T2-weighted MRI lesions was significantly lower in the treated group. Conclusions - The results of our study, which are consistent with those from western studies, show that treatment at an early stage of MS delays conversion to definite MS and has positive effects on MRI outcomes.",
keywords = "Clinically isolated syndrome, Interferon beta-1a, Interferon treatment, Multiple sclerosis",
author = "H. Pakdaman and Sahraian, {M. A.} and A. Fallah and R. Pakdaman and K. Ghareghozli and M. Ghafarpour and E. Rahimian and A. Shirani",
year = "2007",
month = "6",
day = "1",
doi = "10.1111/j.1600-0404.2007.00813.x",
language = "English (US)",
volume = "115",
pages = "429--431",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event

AU - Pakdaman, H.

AU - Sahraian, M. A.

AU - Fallah, A.

AU - Pakdaman, R.

AU - Ghareghozli, K.

AU - Ghafarpour, M.

AU - Rahimian, E.

AU - Shirani, A.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background - A new treatment approach to multiple sclerosis (MS) is the initiation of interferon therapy in the early phase of the disease when a patient presents with clinically isolated syndrome. Aims of the study - The goal of this study was to assess the effect of early treatment on the risk of conversion to clinically definite MS in Iranian patients. Methods - Eligible patients had presented with a first episode of neurological dysfunction suggesting MS within the previous 3 months and had abnormal brain magnetic resonance imaging (MRI). Patients were randomly assigned to receive intramuscular interferon beta 1a 30 μg or placebo once a week for 3 years. Results - Of the 217 patients randomized, 202 patients completed the study; 104 received Avonex and 98 received placebo. Fewer patients converted to clinically definite multiple sclerosis in the treated group than in the placebo group during the study (36.6% vs 58.2%, P < 0.003). The number of active T2-weighted MRI lesions was significantly lower in the treated group. Conclusions - The results of our study, which are consistent with those from western studies, show that treatment at an early stage of MS delays conversion to definite MS and has positive effects on MRI outcomes.

AB - Background - A new treatment approach to multiple sclerosis (MS) is the initiation of interferon therapy in the early phase of the disease when a patient presents with clinically isolated syndrome. Aims of the study - The goal of this study was to assess the effect of early treatment on the risk of conversion to clinically definite MS in Iranian patients. Methods - Eligible patients had presented with a first episode of neurological dysfunction suggesting MS within the previous 3 months and had abnormal brain magnetic resonance imaging (MRI). Patients were randomly assigned to receive intramuscular interferon beta 1a 30 μg or placebo once a week for 3 years. Results - Of the 217 patients randomized, 202 patients completed the study; 104 received Avonex and 98 received placebo. Fewer patients converted to clinically definite multiple sclerosis in the treated group than in the placebo group during the study (36.6% vs 58.2%, P < 0.003). The number of active T2-weighted MRI lesions was significantly lower in the treated group. Conclusions - The results of our study, which are consistent with those from western studies, show that treatment at an early stage of MS delays conversion to definite MS and has positive effects on MRI outcomes.

KW - Clinically isolated syndrome

KW - Interferon beta-1a

KW - Interferon treatment

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=34248673155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248673155&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2007.00813.x

DO - 10.1111/j.1600-0404.2007.00813.x

M3 - Review article

C2 - 17511854

AN - SCOPUS:34248673155

VL - 115

SP - 429

EP - 431

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 6

ER -